Thanks to artists such as America and the Eagles, who blended country, rock 'n' roll, and American roots music, 1972 was a ...
We spoke with Toronto Blue Jays third baseman/outfielder Addison Barger about the steps he's taken during his breakout season and a number of other ...
Hosted on MSN
Jim Croce was one of America’s great musicians—but his story was cut brutally short
Jim Croce was the American folk and rock singer and songwriter who could have had a long and storied career—but his greatness was cut short by one horrific tragedy. Scott Stinson: Speculation swirls ...
** The ink tells the story … We caught up with Ohio State offensive line commitment Jimmy Kalis at Sunday's Under Armour Columbus Camp. We shared a good bit of what Kalis said here. Kalis had a great ...
Genasys Inc. beats earnings expectations. Reported EPS is $0.02, expectations were $-0.03. Operator: Good day, everyone, and thank you all for joining us for today’s Genasys Inc. Fiscal Second Quarter ...
President & Chief Executive Officer — David P. Luci Chief Financial Officer — Robert J. Shawah Executive Chairman — Robert J. DeLuccia Medical Director — Michael A. Silverman David Luci: Thanks, Rob.
Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I'd now like to turn the call over to ...
Earnings call ClearSign Technologies reported Q1 2026 revenue of $200,000, down 50% YoY due to lower parts deliveries, with gross profit impacted by a $410,000 warranty accrual. Management emphasized ...
Acurx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.59. Operator: Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2026 ...
Good day, everyone, and thank you all for joining us for today's Genasys Inc. Fiscal Second Quarter 2026 Conference Call. [Operator Instructions] To get us started with opening remarks and ...
Earnings call Kodiak Gas Services delivered strong Q1 2026 results with total revenue of $346 million (up 5% YoY) and record Adjusted EBITDA of $190 million (up 7% YoY). Management raised guidance for ...
Image source: The Motley Fool. Acurx Pharmaceuticals (NASDAQ:ACXP) emphasized progress in both clinical and regulatory areas, highlighting newly initiated trials and expanded international patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results